Synapse - Martin Tallman

Results (655)

Ratify (Alliance 10603): Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy

Meeting Abstract

Voso, M. T.; Larson, R. A.; Prior, T.; Marcucci, G.; Jones, D.; Krauter, J.; Heuser, M.; Lavorgna, S.; Nomdedeu, J.; Geyer, S. M.; more...
Blood (2018)

Fulltext@MSK | Save

Genomic landscape impacts induction outcome with CPX-351 in patients with acute myeloid leukemia

Meeting Abstract

Talati, C.; Goldberg, A. D.; Desai, P.; Chan, O.; Famulare, C.; Komrokji, R. S.; Kuykendall, A. T.; Fernandez, H. F.; Deutsch, Y. E.; Padron, E.; more...
Blood (2018)

Fulltext@MSK | Save

Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions

Meeting Abstract

Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Pratz, K. W.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; more...
Blood (2018)

Fulltext@MSK | Save

A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): A trial of the ECOG-ACRIN Cancer Research Group (E1912)

Meeting Abstract

Shanafelt, T. D.; Wang, V.; Kay, N. E.; Hanson, C. A.; O'Brien, S. M.; Barrientos, J. C.; Erba, H. P.; Stone, R. M.; Litzow, M. R.; Tallman, M. S.
Blood (2018)

Fulltext@MSK | Save

Prognostic impact of insertion site in acute myeloid leukemia (AML) with FLT3 internal tandem duplication: Results from the ratify study (Alliance 10603)

Meeting Abstract

Rucker, F. G.; Du, L.; Blatte, T. J.; Benner, A.; Krzykalla, J.; Gathmann, I.; Larson, R. A.; Lo-Coco, F.; Amadori, S.; Prior, T. W.; more...
Blood (2018)

Fulltext@MSK | Save

Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant untreated AML: Results from a phase 1 dose escalation and expansion study

Meeting Abstract

Roboz, G. J.; DiNardo, C. D.; Stein, E. M.; de Botton, S.; Mims, A. S.; Prince, G. T.; Altman, J. K.; Arellano, M. L.; Donnellan, W. B.; Erba, H. P.; more...
Blood (2018)

Fulltext@MSK | Save

Acquired resistance to BRAF inhibition in HCL is rare and retreatment with vemurafenib at relapse can induce high response rates: Final results of a phase II trial of vemurafenib in relapsed HCL

Meeting Abstract

Park, J. H.; Lee, J. O.; Stone, R. M.; Saven, A.; Altman, J. K.; Grever, M. R.; Rai, K. R.; Vemuri, S.; Abdel-Wahab, O. I.; Tallman, M. S.
Blood (2018)

Fulltext@MSK | Save

Metforminintreatment overcomes ATRA-resistance in acute promyelocytic leukemia FOXO3A expression

Meeting Abstract

Pereira-Martins, D. A.; Ortiz, C.; Franca-Neto, P. L.; Weinhauser, I.; Schiavinato, J. L.; Palma, P. V. B.; Bonaldo, C.; Koury, L. C. A.; Do Nascimento, M. C.; Melo, R. A. M.; more...
Blood (2018)

Fulltext@MSK | Save

Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia